A Virtual Clinical Trial to Examine the Effect of Magnesium Choline Citrate on Cognitive Function and Anxiety in Healthy Adolescents and Adults

Sponsor
Nutrisol, LLC
Study ID
NCT07685613
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Anxiety
  • Cognitive Function

Eligibility Criteria

Sex
ALL
Age
8 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Magnesium Choline Citrate — DIETARY_SUPPLEMENT
    Participants will be instructed to take two capsules twice per day with food starting on Day 1.
  • Placebo — DIETARY_SUPPLEMENT
    Participants will be instructed to take two capsules twice per day with food starting on Day 1

Study Details

The goal of this clinical trial is to examine the effect of Magnesium Choline Citrate on cognitive function and anxiety in healthy adolescents and adults. The main questions it aims to answer are: * What is the change in cognitive function, as assessed by the PROMIS Cognitive Function- Short Form 8a (≥18 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo? * What is the change in cognitive function, as assessed by the Pediatric Cognitive Function - Short Form 7a (8 - 17 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo? Researchers will compare Magnesium Choline Citrate with placebo to evaluate its effects on cognitive function and anxiety symptoms. Participants will be asked to: * Consume either Magnesium Choline Citrate or placebo for 84 days * Complete questionnaires (PROMIS Cognitive Function- Short Form 8a/Pediatric Cognitive Function - Short Form 7a, and PROMIS Emotional Distress - Anxiety - Short Form 8a/Pediatric Anxiety - Short Form 8a) * Complete a study diary weekly

Key Dates

First listed
Jul 6, 2026
Start date
Sep 30, 2026
Status verified
Jun 2026
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Magnesium Choline Citrate
  • Placebo Comparator: Placebo

Primary Outcome Measure

PROMIS Cognitive Function- Short Form 8a (baseline to day 84) [ Time Frame: Baseline (day 1) to day 84 ]

Central Contacts

Related Studies